3 most recent filings and news items mentioning CDNA. Updated every 60 seconds.
Earnings|GuidanceJul 30, 2026Positive
Second quarter 2026 revenue increased 52% year-over-year to $132 million. The company raised its 2026 revenue guidance to $490M-$500M and AEBITDA guidance to $66M-$78M. The growth was driven by strong testing services volume and revenue expansion.
View filing at SEC.gov →
M&AJul 7, 2026Neutral
CareDx closed the sale of its Lab Products business to Eurobio Scientific for $171.2 million. This divestiture sharpens the company's focus on its core U.S. precision medicine services and operating model.
View filing at SEC.gov →
OtherJun 15, 2026Neutral
CareDx's board approved Amendment No. 2 to its 2024 Equity Incentive Plan, increasing the share reserve available for awards to 6.7 million shares, pending stockholder approval. This expansion allows the company greater flexibility in compensating employees and executives through
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.